Literature DB >> 6683999

cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.

A Veronesi, V Zagonel, M Santarossa, U Tirelli, E Galligioni, M G Trovo', S Tumolo, E Grigoletto.   

Abstract

From December 1981 to November 1982, a consecutive series of 37 patients with advanced non-oat cell bronchogenic carcinoma were treated with cis-platinum and etoposide in doses of 20 mg/m2 and 75 mg/m2, respectively, for 5 consecutive days every 3 weeks. Among the 33 evaluable patients, one complete response, 11 partial responses, five minor responses, seven unchanged states, and nine cases of progression were noted. Median duration of response was 30+ weeks. Toxicity was significant, but no treatment-related deaths were encountered. Combined cis-platinum and etoposide can provide significant palliation in approximately one-third of patients with the doses and schedule used.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683999     DOI: 10.1007/bf00257414

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma.

Authors:  A Goldhirsch; R Joss; F Cavalli; K W Brunner
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

2.  Treatment of inoperable non-small-cell bronchogenic carcinoma with etoposide and cis-platinum.

Authors:  P S Mitrou; M Fischer; I Weissenfels; V Diehl; C Gropp; A Liesenfeld; M Schmidt; W E Berdel; U Fink; M Graubner
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

3.  Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma.

Authors:  J Klastersky; E Longeval; C Nicaise; D Weerts
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

4.  Phase II trial of VP-16-213 in non-small-cell lung cancer.

Authors:  L M Itri; R J Gralla; R A Chapman; D P Kelsen; E S Casper; R B Golbey
Journal:  Am J Clin Oncol       Date:  1982-02       Impact factor: 2.339

5.  VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  R T Eagan; J N Ingle; E T Creagan; S Frytak; L K Kvols; J Rubin; R T McMachon
Journal:  Cancer Treat Rep       Date:  1978-05

6.  Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma.

Authors:  S E Vogl; M Berenzweig; F Camacho; E Greenwald; B H Kaplan
Journal:  Cancer       Date:  1982-07-01       Impact factor: 6.860

7.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

8.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

9.  High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).

Authors:  R De Jager; E Longeval; J Klastersky
Journal:  Cancer Treat Rep       Date:  1980

10.  Evaluation of response criteria in advanced lung cancer.

Authors:  R T Eagan; T R Fleming; V Schoonover
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

View more
  2 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer.

Authors:  F Figoli; A Veronesi; M G Trovo; D Errante; M Della Valentina; V Zagonel; R Talamini; M D Magri; S Monfardini
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.